Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894355 | 0.89 | MDM2 (0.56) | MDM2PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL27862823 | 0.87 | MDM2 (0.56) | MDM2RIPK1GABRA2GABRB2POLB | |
| SCHEMBL1442682 | 0.86 | MDM2 (0.72) | MDM2RIPK1GABRA2GABRB2 | |
| SCHEMBL1437198 | 0.85 | MDM2 (0.54) | MDM2PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1440068 | 0.83 | MDM2 (0.57) | MDM2GABRA2GABRB2 | |
| SCHEMBL1437170 | 0.81 | MDM2 (0.56) | MDM2CNR2GABRA2GABRB2CNR1 | |
| SCHEMBL9893757 | 0.79 | MDM2 (0.62) | MDM2RIPK1 | |
| SCHEMBL1437066 | 0.78 | MDM2 (0.56) | MDM2RIPK1GABRA2GABRB2CTSA | |
| SCHEMBL9893965 | 0.77 | MDM2 (0.48) | MDM2RIPK1CNR2GABRA2GABRB2 | |
| SCHEMBL1437279 | 0.75 | MDM2 (0.40) | MDM2PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885PDE4B 3755/4885PDE4D 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.